ALK dreams big in the US, but patients stayed away during corona-struck quarter: "Zero – as in zero – patients went to the doctor's in the first 6-7 weeks"
The Covid-19 outbreak provides some significant challenges for allergy company ALK, especially on the US market, where the company has placed its bets in recent years. This prompts CEO Carsten Hellmann to give up a goal of 10 percent growth in the US in 2020.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.